Abbott FlexNav
Abbott won CE Mark approval in March for the FlexNav delivery system for its Portico transcatheter aortic valve implantation (TAVI) system.
Abbott touted the system as another tool for doctors to treat patients requiring a transcatheter aortic valve implant by incorporating stability, predictability and placement accuracy in the procedure.
Clinical study data presented in September 2019 revealed that in a U.S. trial, patients who received a Portico valve implanted with FlexNav experienced zero deaths, zero strokes and low rates of major vascular complications and new permanent pacemaker implants after 30 days.